Literature DB >> 8543305

The role of microvascular injury in the pathogenesis of cutaneous lesions of dermatomyositis.

A N Crowson1, C M Magro.   

Abstract

Although microvascular injury has been postulated as the pathogenetic basis of skeletal muscle injury in dermatomyositis (DM), its role in the genesis of the skin lesions, which are said to be difficult to distinguish light microscopically from systemic lupus erythematosus (SLE) and subacute lupus erythematosus (SCLE), has not been analyzed. The authors' intention was to assess the role of microvascular injury in the pathogenesis of skin lesions in DM, SLE, and SCLE. Light microscopic features of biopsies of lesional skin from 20 patients with myopathic DM and 11 with amyopathic DM were compared to eight lesional skin biopsies from eight patients with SLE and 12 lesional skin biopsies from 12 patients with SCLE. Vascular density was compared in the three groups using an immunohistochemical preparation with an antibody to factor VIII. In 12 biopsies from the DM group, and in 19 of 20 lupus erythematosus (LE) specimens, frozen tissue was available. An indirect immunofluorescence methodology was used to detect C5b-9 deposition, and direct immunofluorescence studies for other immunoreactants were performed in standard fashion. Compared with LE, lesions of DM showed a greater degree of endothelial injury, vascular ectasia, and vascular fibrin deposition; there were no differences between myopathic versus amyopathic DM. C5b-9 deposition in vessels was significantly greater in DM than in LE. The superficial vascular plexus density was reduced in lesions of DM versus LE control groups with the greatest reduction observed in myopathic DM. Epithelial injury and mucin was greatest in myopathic DM. Microvascular injury is the apparent pathophysiological basis of skin lesions in DM. Careful attention to microvascular pathology enables distinction of DM from SLE and SCLE. Indirect immunofluorescence testing using a monoclonal antibody to C5b-9 is a valuable tool to distinguish DM from LE in biopsies of lesional skin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8543305     DOI: 10.1016/s0046-8177(96)90132-x

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  16 in total

Review 1.  Dermatomyositis.

Authors:  M S Krathen; D Fiorentino; V P Werth
Journal:  Curr Dir Autoimmun       Date:  2008

Review 2.  Amyopathic dermatomyositis.

Authors:  N J Olsen; J H Park; L E King
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

Review 3.  Dermatomyositis and type 1 interferons.

Authors:  Steven A Greenberg
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

Review 4.  The Immune Response and the Pathogenesis of Idiopathic Inflammatory Myositis: a Critical Review.

Authors:  Angela Ceribelli; Maria De Santis; Natasa Isailovic; M Eric Gershwin; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

5.  Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease.

Authors:  Neera S Narang; Livia Casciola-Rosen; Shufeng Li; Lorinda Chung; David F Fiorentino
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-05       Impact factor: 4.794

6.  The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study.

Authors:  David Fiorentino; Lorinda Chung; Jeff Zwerner; Antony Rosen; Livia Casciola-Rosen
Journal:  J Am Acad Dermatol       Date:  2011-04-29       Impact factor: 11.527

7.  Disease-associated increased HIF-1, alphavbeta3 integrin, and Flt-1 do not suffice to compensate the damage-inducing loss of blood vessels in inflammatory myopathies.

Authors:  Yrjö T Konttinen; Zygmunt Mackiewicz; Danute Povilenaite; Antti Sukura; Mika Hukkanen; Ismo Virtanen
Journal:  Rheumatol Int       Date:  2003-09-12       Impact factor: 2.631

Review 8.  [Dermatomyositis].

Authors:  G Stoltenburg-Didinger; E Genth
Journal:  Z Rheumatol       Date:  2009-06       Impact factor: 1.372

9.  Treatment of Susac's Syndrome.

Authors:  Robert M Rennebohm; Robert A Egan; John O Susac
Journal:  Curr Treat Options Neurol       Date:  2008-01       Impact factor: 3.598

10.  Polymyositis and dermatomyositis: Disease spectrum and classification.

Authors:  Siba P Raychaudhuri; Anupam Mitra
Journal:  Indian J Dermatol       Date:  2012-09       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.